Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMMB NASDAQ:ELUT NASDAQ:LIXT NASDAQ:MIRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMMBChemomab Therapeutics$1.69+3.7%$1.70$1.35▼$5.88$12.16M0.5164,479 shs22,782 shsELUTElutia$1.00+2.5%$1.11$0.50▼$2.64$42.78M0.75195,245 shs46,550 shsLIXTLixte Biotechnology$4.03-10.2%$3.10$0.64▼$6.26$47.24M1.0459,542 shs35,917 shsMIRAMIRA Pharmaceuticals$1.02$1.11$0.90▼$2.45$42.86M1.48154,182 shs66,666 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMMBChemomab Therapeutics+1.36%+10.51%+4.49%0.00%-69.36%ELUTElutia-3.40%-2.43%-16.61%-1.66%-48.65%LIXTLixte Biotechnology+33.23%+24.72%+47.21%+39.44%+253.54%MIRAMIRA Pharmaceuticals-1.92%+0.99%-8.11%-15.70%-12.82%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMMBChemomab Therapeutics$1.69+3.7%$1.70$1.35▼$5.88$12.16M0.5164,479 shs22,782 shsELUTElutia$1.00+2.5%$1.11$0.50▼$2.64$42.78M0.75195,245 shs46,550 shsLIXTLixte Biotechnology$4.03-10.2%$3.10$0.64▼$6.26$47.24M1.0459,542 shs35,917 shsMIRAMIRA Pharmaceuticals$1.02$1.11$0.90▼$2.45$42.86M1.48154,182 shs66,666 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMMBChemomab Therapeutics+1.36%+10.51%+4.49%0.00%-69.36%ELUTElutia-3.40%-2.43%-16.61%-1.66%-48.65%LIXTLixte Biotechnology+33.23%+24.72%+47.21%+39.44%+253.54%MIRAMIRA Pharmaceuticals-1.92%+0.99%-8.11%-15.70%-12.82%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMMBChemomab Therapeutics 2.00Hold$25.001,378.42% UpsideELUTElutia 2.50Moderate Buy$6.00500.00% UpsideLIXTLixte Biotechnology 1.00SellN/AN/AMIRAMIRA Pharmaceuticals 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest CMMB, LIXT, ELUT, and MIRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2026ELUTElutia Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)3/27/2026MIRAMIRA Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMMBChemomab TherapeuticsN/AN/AN/AN/A$2.00 per shareN/AELUTElutia$12.29M3.48N/AN/A$0.65 per share1.54LIXTLixte BiotechnologyN/AN/AN/AN/A$1.05 per shareN/AMIRAMIRA PharmaceuticalsN/AN/AN/AN/A$0.25 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMMBChemomab Therapeutics-$8.99M-$2.56N/AN/AN/AN/A-103.85%-90.44%5/7/2026 (Estimated)ELUTElutia$53.38M$0.821.22N/AN/A282.63%N/A-49.57%5/14/2026 (Estimated)LIXTLixte Biotechnology-$6.01M-$1.24N/AN/AN/AN/A-242.85%-115.18%5/11/2026 (Estimated)MIRAMIRA Pharmaceuticals-$10.44M-$1.53N/AN/AN/AN/A-210.90%-198.94%6/3/2026 (Estimated)Latest CMMB, LIXT, ELUT, and MIRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026CMMBChemomab Therapeutics-$0.04N/AN/AN/AN/AN/A5/14/2026Q1 2026ELUTElutia-$0.15N/AN/AN/A$3.00 millionN/A3/19/2026Q4 2025CMMBChemomab Therapeutics-$0.20-$0.24-$0.04-$0.24N/AN/A3/11/2026Q4 2025ELUTElutia-$0.14-$0.14N/A$1.48$3.30 million$3.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCMMBChemomab TherapeuticsN/AN/AN/AN/AN/AELUTElutiaN/AN/AN/AN/AN/ALIXTLixte BiotechnologyN/AN/AN/AN/AN/AMIRAMIRA PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMMBChemomab TherapeuticsN/A9.089.08ELUTElutiaN/A2.222.12LIXTLixte BiotechnologyN/A3.883.88MIRAMIRA PharmaceuticalsN/A15.7515.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMMBChemomab Therapeutics46.05%ELUTElutia74.03%LIXTLixte Biotechnology5.10%MIRAMIRA Pharmaceuticals35.16%Insider OwnershipCompanyInsider OwnershipCMMBChemomab Therapeutics11.91%ELUTElutia27.60%LIXTLixte Biotechnology9.50%MIRAMIRA Pharmaceuticals6.65%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMMBChemomab Therapeutics207.19 million6.34 millionNot OptionableELUTElutia18042.78 million30.98 millionNot OptionableLIXTLixte Biotechnology411.62 million10.51 millionNot OptionableMIRAMIRA Pharmaceuticals242.02 million39.23 millionNot OptionableCMMB, LIXT, ELUT, and MIRA HeadlinesRecent News About These CompaniesVisionstate Reports 27% Q2 Revenue Growth as MIRA Platform Gains Traction1 hour ago | newsfilecorp.comNWhat's going on with MIRA Pharma stock Tuesday?March 24, 2026 | msn.comMIRA Pharmaceuticals Highlights Encouraging Safety Data for Mira-55March 23, 2026 | tipranks.comMIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical StudiesMarch 23, 2026 | accessnewswire.comAMIRA Pharmaceuticals completes dosing in Ketamir-2 Phase I trialMarch 5, 2026 | yahoo.comMIRA Pharmaceuticals Completes Phase 1 Dosing of Ketamir-2March 4, 2026 | accessnewswire.comAMIRA Completes Phase 1 Trial of Ketamir-2 TherapyMarch 3, 2026 | tipranks.comWhy MIRA Pharmaceuticals, Inc.’s (MIRA) Stock Is Down 13.39%March 3, 2026 | aaii.comAVisionstate Repositions Under MIRA Compliance Platform and Reports Subscription GrowthFebruary 19, 2026 | newsfilecorp.comNMIRA Pharmaceuticals Initiates Final Cohort of Ketamir-2 Phase 1 Clinical Study as Company Prepares for Phase 2a StudyFebruary 3, 2026 | accessnewswire.comAMIRA Pharmaceuticals Advances Ketamir-2 Phase 1 to Final CohortFebruary 2, 2026 | tipranks.comMIRA Pharmaceuticals Expands Stock Offering by $15MDecember 5, 2025 | tipranks.comMIRA Pharmaceuticals (MIRA) Price Target Decreased by 83.10% to 3.06October 29, 2025 | msn.comMIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a IndicationOctober 24, 2025 | accessnewswire.comAMIRA Pharmaceuticals Advances Ketamir-2 Clinical TrialsOctober 23, 2025 | tipranks.comMira Pharmaceuticals announces preclinical data on oral Mira-55October 17, 2025 | msn.comMIRA Pharmaceuticals Inc.October 16, 2025 | barrons.comMira Pharmaceuticals stock soars after positive pain treatment study resultsOctober 16, 2025 | za.investing.comMira Pharmaceuticals (MIRA) Stock Rockets After Pain Drug Tops Morphine in TrialsOctober 16, 2025 | blockonomi.comMIRA Pharmaceuticals Sells Shares at 66% PremiumOctober 16, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCMMB, LIXT, ELUT, and MIRA Company DescriptionsChemomab Therapeutics NASDAQ:CMMB$1.69 +0.06 (+3.74%) As of 11:01 AM Eastern This is a fair market value price provided by Massive. Learn more.Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.Elutia NASDAQ:ELUT$1.00 +0.02 (+2.49%) As of 10:55 AM Eastern This is a fair market value price provided by Massive. Learn more.Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.Lixte Biotechnology NASDAQ:LIXT$4.03 -0.46 (-10.24%) As of 11:03 AM Eastern This is a fair market value price provided by Massive. Learn more.LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.MIRA Pharmaceuticals NASDAQ:MIRA$1.02 0.00 (0.00%) As of 10:58 AM Eastern This is a fair market value price provided by Massive. Learn more.MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
